Psilocybin Treatment Guide – Understanding Psychedelic-Assisted Therapy
A Comprehensive Guide to Psilocybin-Assisted Psychotherapy
Welcome to Buy Psychedelic Mushroom UK, your trusted source for educational information on psychedelic research. This guide provides an overview of psilocybin-assisted psychotherapy (PAP) – a treatment approach that combines the administration of psilocybin with structured psychological support. It is intended for educational and informational purposes only and does not constitute medical advice.
What is Psilocybin-Assisted Psychotherapy?
Psilocybin-assisted psychotherapy (PAP) is a treatment model that combines the administration of psilocybin – the active compound found in psilocybin mushrooms – with structured psychotherapeutic support. Unlike conventional pharmacotherapy, where a patient takes medication independently, PAP integrates the psychedelic experience into a therapeutic framework designed to facilitate psychological healing and personal insight.
The approach is gaining recognition as a potential treatment for a range of mental health conditions. The Royal College of Psychiatrists has published a report on the safety and efficacy of psychedelics and related substances (PARS) as medical treatments for mental illness, concluding that initial studies show these substances could potentially help treat anxiety disorders, depression, PTSD, and substance misuse .
However, with the exception of ketamine, these substances are not legally available as treatments outside of research settings in the UK. The Royal College emphasises that there is not enough high-quality evidence to support their routine use in clinical settings .
Safety, Risks, and Contraindications
Potential Adverse Events
While psilocybin-assisted therapy has shown promising safety profiles in clinical trials, potential adverse events can occur. Common adverse events include :
Physical: Headache and nausea
Psychological: Anxiety, confusion, and fear (often part of the therapeutic process)
Serious Adverse Events: Severe psychological distress, panic reactions, and transient psychotic states can occur. These are generally reduced by good preparation and screening
Contraindications
Individuals with the following conditions are generally not suitable for psilocybin-assisted therapy:
Personal History of Psychosis: Generally considered an absolute contraindication
Bipolar Disorder: May trigger mania
First-Degree Family History of Psychotic Disorders: Strong relative contraindication
Cardiovascular Conditions: Requires specialist assessment due to potential increases in heart rate and blood pressure
The Science Behind Psilocybin Treatment
How Psilocybin Works in the Brain
Psilocybin is converted in the body to psilocin, which acts as a serotonin receptor agonist, primarily targeting 5-HT2A receptors in the brain . This interaction produces alterations in perception, mood, and cognition, and is thought to facilitate therapeutic change by temporarily disrupting rigid patterns of thought and behaviour.
Psilocybin affects processes in the brain which can allow people to feel and think differently about themselves, their experiences, and the world around them. The Royal College of Psychiatrists notes that this can help facilitate therapeutic change which may not have been possible through more conventional treatments .
Clinical Research and Evidence
The scientific evidence for psilocybin-assisted therapy has grown substantially in recent years. A phase 2b randomized controlled trial published in 2025 found that psilocybin-assisted psychotherapy produced significantly greater reductions in depression and anxiety symptoms compared to placebo in individuals with life-threatening illnesses .
Key findings from this trial include:
Significant reduction in depressive symptoms measured by the Hospital Anxiety and Depression Scale (HADS) at 6-7 weeks post-dose
Durable benefits sustained at 26 weeks
Enhanced spiritual well-being and quality of life
A systematic review and meta-analysis published in 2023 found that psilocybin therapy showed promise for depressive symptoms, though the authors noted the need for larger, more rigorous trials
Drug Interactions
Antidepressants are generally accepted to be co-administered in some protocols, but MAOIs are contraindicated with a wash-out time suggested . Most clinical trials require a supervised taper and washout of SSRIs and SNRIs before psilocybin dosing
How Psilocybin-Assisted Psychotherapy Works
The Three-Phase Treatment Model
Psilocybin-assisted psychotherapy typically follows a structured three-phase model: preparation, dosing, and integration.
Preparation Phase
The preparation phase involves establishing a therapeutic alliance and preparing the patient for the psychedelic experience. This includes:
Psychiatric Assessment: A comprehensive evaluation focusing on diagnosis, current pharmacotherapy, and suitability for PAP .
Informed Consent: Psychoeducational material is provided covering expected effects, risks, and the treatment process .
Intention Setting: Exploration of goals, motivations, and expectations .
Skills Training: Techniques such as grounding, body awareness, and navigating altered states .
At least two preparation sessions are typically required, with a total duration of approximately 180 minutes .
Dosing Phase
The dosing session takes place in a calm, comfortable, aesthetically appealing room. Key features include:
Full Physical and Mental State Assessment: Conducted prior to dosing, with focus on vital signs, pregnancy, mental state stability, and substance use .
Presence of a Therapist: At least one therapist is present throughout the session to provide support .
Structured Use of Music: Music is used during dosing sessions to support the therapeutic process .
Monitoring: Vital signs are monitored at four defined points: baseline, peak, plateau, and resolution .
For low-dose sessions, patients remain in the clinical setting for a minimum of four hours; for high-dose sessions, this extends to at least six hours .
Integration Phase
Integration sessions help patients consolidate insights and incorporate them into daily life. This involves:
Minimum of Two Integration Sessions: Within ten days following dosing, with the first occurring within 72 hours and the second within 10 days .
Focus on Consolidation: Linking insights to clinical issues and personal narratives, and supporting meaning-making and behavioural change .
Weekly Follow-Up: Continues for one month, after which care is transferred back to the patient’s usual team .
Psilocybin Dosing Structure
Dosing in clinical settings is weight-based, typically 0.2–0.4 mg/kg administered orally. The table below summarises the dosing hierarchy used in clinical practice :
| Category | Dose | Clinical Effect |
|---|---|---|
| Microdose | <2.5 mg | Sub-perceptual; no significant perceptual changes |
| Low Dose | 5–15 mg | Mild perceptual changes, increased introspection, early insight |
| Standard (Therapeutic) | 20–25 mg | Full psychedelic experience; primary antidepressant effect range |
| High Dose | 25–35 mg | Ego dissolution, potential for deep psychological insights |
| Supra-therapeutic | >35 mg | Research and safety studies only; not for routine clinical use |
A single-session maximum of 35 mg typically applies across all pathways, and the first dose a patient receives may not exceed 25 mg .
The Role of Psychotherapy in Psilocybin Treatment
The therapeutic relationship is central to psilocybin-assisted psychotherapy. As Dr Jo O’Reilly, Chair of the Royal College of Psychiatrists’ Medical Psychotherapy Faculty, notes:
“Patients can be in a particularly vulnerable state when under the influence of these substances and the therapeutic relationship is key to safe and effective practice… They should be supported through every step of their treatment, from initial preparation sessions to follow-up care” .
The therapist’s role includes:
Providing a Safe Container: Creating a supportive, non-judgmental environment
Offering Support During Challenging States: Using grounding, breathwork, relaxation methods, and supportive touch when appropriate
Facilitating Integration: Helping patients make sense of their experience and translate insights into lasting change
The Therapist Manual for Psilocybin-Assisted Therapy
A comprehensive therapist manual for psilocybin-assisted therapy of treatment-resistant major depression (EPIsoDE trial) has been made publicly available, providing a structured therapeutic framework . The manual outlines:
Therapist qualifications and training procedures
Use of a therapist dyad model to ensure treatment safety and efficacy
Detailed guidance on preparatory sessions, dosing sessions, and integration sessions
Structured use of music during dosing sessions
Safety monitoring procedures including psychological and cardiovascular assessments
Frequently Asked Questions
What conditions can psilocybin-assisted therapy treat?
Research is exploring the use of psilocybin-assisted therapy for a range of mental health conditions, including treatment-resistant depression, anxiety disorders, PTSD, and substance misuse. However, the Royal College of Psychiatrists concludes that there is not enough high-quality evidence to support routine use in clinical settings outside of research .
What is the difference between microdosing and therapeutic dosing?
Microdosing typically involves sub-perceptual doses of less than 2.5 mg, while therapeutic dosing (20-35 mg) produces a full psychedelic experience designed for psychological insight and healing
Can I access psilocybin therapy privately?
Currently, psilocybin-assisted therapy is only available through clinical trials and research studies in the UK. The Royal College of Psychiatrists recommends that patients should be supported through every step of treatment, from preparation to follow-up care
Psilocybin-assisted psychotherapy represents a promising frontier in mental health treatment, with a growing body of evidence supporting its potential for conditions such as depression, anxiety, and PTSD. The Royal College of Psychiatrists has called for more high-quality research into the use of psychedelics within clinical settings to address concerns around their safety, efficacy, and long-term use .
For those interested in learning more, the Psychedelic Therapy Workbook provides an evidence-based guide to integrating psychedelic experiences into daily life, covering topics such as set and setting, intention setting, and integration practices
At Buy Psychedelic Mushroom UK, we prioritise education and research support. Our products are intended for research, collection, and educational purposes only.